Aus study flags mortality risk with colchicine for cardiac patients
The randomised trial examining clinical utility of colchicine in acute coronary syndrome failed to find a benefit in reduced CV events
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
An Australian trial of colchicine added to standard medical therapy failed to significantly affect CV outcomes in patients with acute coronary syndromes (ACS), researchers say.
And the study, across 17 hospitals, found a higher rate of total and non-cardiovascular deaths among the patients receiving colchicine, the European Society of Cardiology virtual congress has heard.
The COPS randomised trial of 795 patients demonstrated that addition of colchicine (0.5mg twice daily for first month, then 0.5mg daily for 11 months) to standard medical therapy did not significantly affect cardiovascular outcomes compared with placebo.
